7 pending office actions • 6 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Oyster Point Pharma, Inc. | 2 |
| Meda Pharma S.p.A. | 1 |
| Mylan Laboratories Ltd. | 1 |
| Meda Pharma S.p.A. | 1 |
| Viatris Inc. | 1 |
| Viatris Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18705156 | Untitled | Meda Pharma S.p.A. | CHI, AMANDA LYNN | 1613 | Non-Final OA | |
| 19285330 | PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAM | Mylan Laboratories Ltd. | WILSON, JERICA KATLYNN | 1621 | Non-Final OA | Jul 30, 2025 |
| 19169817 | USE OF VARENICLINE FOR TREATING OCULAR CONDITIONS | Oyster Point Pharma, Inc. | KASSA, TIGABU | 1619 | Final Rejection | Apr 03, 2025 |
| 18580373 | COMBINATION FOR USE FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, CARDIOVASCULAR DISEASE AND METABOLIC SYNDROME | Meda Pharma S.p.A. | MI, QIUWEN | 1655 | Non-Final OA | Jan 18, 2024 |
| 18579110 | PROCESS FOR THE SYNTHESIS OF 4-((R)-2-{[6-((S)-3-METHOXY-PYRROLIDIN-1-YL)-2-PHENYL-PYRIMIDINE-4-CARBONYL]-AMINO}-3-PHOSPHONO-PROPIONYL)-PIPERAZINE-1-CARBOXYLIC ACID BUTYL ESTER | Viatris Inc. | HEASLEY, MEGHAN CHRISTINE | 1626 | Non-Final OA | Jan 12, 2024 |
| 18016299 | AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING A P2Y12 RECEPTOR ANTAGONIST | Viatris Inc. | KENYON, JOHN S | 1625 | Non-Final OA | Jan 13, 2023 |
| 18049815 | LOCAL ADMINISTRATION OF NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR THE INHIBITION OF CORONAVIRUS INFECTIONS | Oyster Point Pharma, Inc. | HAVLIN, ROBERT H | 1626 | Non-Final OA | Oct 26, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial